2
Orphan Designations
0 approved
0
FDA Approvals
1
Active Trials
200 recruiting
3
Rare Diseases
across 6 areas
0
News (30d)
Quiet
Galapagos NV is a company with 2 orphan drug designations across 3 rare diseases. Active clinical trials in 1 indication.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| idiopathic pulmonary fibrosis | 2-((2-ethyl-6-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)-piperazin-1-yl)-8-methylimidazo[1,2-a]pyridin-3-yl)-(methyl)amino)-4-(4-fluorophenyl)-thiazole-5-carbonitrile | Des.TrialAppr. |
| lupus erythematosus | - | Des.TrialAppr. |
| systemic sclerosis | Ziritaxestat | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
21
overlap in 2+ diseases
0/3
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
21
overlap in 2+ diseases
0/3
candidate diseases
0
avg importance: 0
0
affecting portfolio